Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

Rhea-AI Summary

Provectus Biopharmaceuticals (OTCQB: PVCT) announced the publication of preclinical research on PV-10 for head and neck squamous cell carcinoma (HNSCC) in Molecular Cancer Therapeutics. The research, conducted by Dr. Christine Chung's team at Moffitt Cancer Center, revealed novel mechanistic findings about PV-10's ability to trigger immunogenic cell death in HNSCC through endoplasmic reticulum stress and apoptosis.

The company plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt Cancer Center later in 2025. PV-10 is Provectus's investigational cancer immunotherapy formulated from pharmaceutical-grade rose bengal sodium (RBS).

Positive

• None.

Negative

• Research still in preclinical stage, far from potential commercialization
• Phase 1 trial not yet initiated, pending future implementation

KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”).

The study, published in Molecular Cancer Therapeutics, highlights novel mechanistic findings that could support future clinical development of PV-10 in locally recurrent HNSCC. The article, titled “PV-10 triggers immunogenic cell death in head and neck squamous cell carcinoma via endoplasmic reticulum stress and apoptosis,” is available here.

PV-10, Provectus’s investigational cancer immunotherapy, is formulated from the Company’s pharmaceutical-grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”).

Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus, commented, “This important, multi-year research effort funded by the Chung Lab at Moffitt adds to our understanding of PV-10’s mechanistic effects—specifically its ability to induce immunogenic cell death in HNSCC. These results align with our broad immunotherapy platform, including a planned Phase 1 trial potentially later this year of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt.”

Mr. Rodrigues added, “We’re deeply grateful to Dr. Chung and her Moffitt colleagues for their scientific rigor and dedication. Their work reflects the broader momentum building around our pharmaceutical-grade RBS platform.”

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecules called halogenated xanthenes. Provectus’s lead molecule is named Rose Bengal Sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.

Forward Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

• The Company’s Annual Report on Form 10-K for the period ended December 31, 2024, and
• Provectus’s Quarterly Report on Form 10-Q for the period ended March 31, 2025.

Contacts:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999

Investor Relations & Media
Susan Xu
sxu@allianceadvisors.com
(778) 323-0959

FAQ

What did Provectus Biopharmaceuticals (PVCT) announce about PV-10 research?

Provectus announced the publication of preclinical research in Molecular Cancer Therapeutics showing PV-10's ability to trigger immunogenic cell death in head and neck squamous cell carcinoma through endoplasmic reticulum stress and apoptosis.

When will Provectus (PVCT) begin Phase 1 trials for PV-10?

The company plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt Cancer Center potentially later in 2025.

What is PV-10 and how does it work in cancer treatment?

PV-10 is Provectus's investigational cancer immunotherapy formulated from pharmaceutical-grade rose bengal sodium (RBS). It works by triggering immunogenic cell death in cancer cells through endoplasmic reticulum stress and apoptosis.

Who conducted the research on PV-10 for head and neck cancer?

The research was conducted by Dr. Christine Chung and her team at Moffitt Cancer Center in Tampa, Florida.

What type of cancer is Provectus (PVCT) targeting with PV-10?

The research focuses on head and neck squamous cell carcinoma (HNSCC), with planned clinical trials for pre-operative penile squamous cell carcinoma.